Blood-Based Biomarkers for the Optimization of Anti-Angiogenic Therapies
Abstract
:1. Introduction
2. Angiogenic Growth Factors, Soluble Receptors and Other Proteins
3. Molecular Markers
4. Cellular Markers
5. CECs as Surrogate Markers of Angiogenesis and Anti-angiogenic Drug Activity in Medical Oncology
6. Blood Pressure as a Biomarker
7. Conclusions and Future Perspectives
References
- Kerbel, R.S. Tumor angiogenesis. N. Engl. J. Med. 2008, 358, 2039–2049. [Google Scholar] [CrossRef]
- Asahara, T.; Bauters, C.; Zheng, L.P.; Takeshita, S.; Bunting, S.; Ferrara, N.; Symes, J.F.; Isner, J.M. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation 1995, 92, 365–371. [Google Scholar] [CrossRef]
- Cheng, N.; Brantley, D.M.; Liu, H.; Lin, Q.; Enriquez, M.; Gale, N.; Yancopoulos, G.; Cerretti, D.P.; Daniel, T.O.; Chen, J. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. Mol. Cancer Res. 2002, 1, 2–11. [Google Scholar] [CrossRef] [Green Version]
- Holash, J.; Maisonpierre, P.C.; Compton, D.; Boland, P.; Alexander, C.R.; Zagzag, D.; Yancopoulos, G.D.; Wiegand, S.J. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999, 284, 1994–1998. [Google Scholar] [CrossRef]
- Kano, M.R.; Morishita, Y.; Iwata, C.; Iwasaka, S.; Watabe, T.; Ouchi, Y.; Miyazono, K.; Miyazawa, K. VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFRbeta signalling. J. Cell. Sci. 2005, 118, 3759–3768. [Google Scholar] [CrossRef]
- Noguera-Troise, I.; Daly, C.; Papadopoulos, N.J.; Coetzee, S.; Boland, P.; Gale, N.W.; Lin, H.C.; Yancopoulos, G.D.; Thurston, G. Blockade of Dll4 inhibits tumor growth by promoting non-productive angiogenesis. Nature 2006, 444, 1032–1037. [Google Scholar] [CrossRef]
- Richardson, T.P.; Peters, M.C.; Ennett, A.B.; Mooney, D.J. Polymeric system for dual growth factor delivery. Nat. Biotechnol. 2001, 19, 1029–1034. [Google Scholar] [CrossRef]
- Ridgway, J.; Zhang, G.; Wu, Y.; Stawicki, S.; Liang, W.C.; Chanthery, Y.; Kowalski, J.; Watts, R.J; Callahan, C.; Kasman, I.; Singh, M.; Chien, M.; Tan, C.; Hongo, J.A.; de Sauvage, F.; Plowman, G.; Yan, M. Inhibition of Dll4 signalling inhibits tumor growth by deregulating angiogenesis. Nature 2006, 444, 1083–1087. [Google Scholar] [CrossRef]
- Hellstrom, M.; Phng, L.K.; Hofmann, J.J.; Wallgard, E.; Coultas, L.; Lindblom, P.; Alva, J.; Nilsson, AK.; Karlsson, L.; Gaiano, N.; Yoon, K.; Rossant, J.; Iruela-Arispe, M.L.; Kalén, M.; Gerhardt, H.; Betsholtz, C. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 2007, 445, 776–780. [Google Scholar] [CrossRef]
- Sainson, R.C.; Harris, A.L. Anti-Dll4 therapy: can we block tumor growth by increasing angiogenesis? Trends Mol. Med. 2007, 13, 389–395. [Google Scholar] [CrossRef]
- Siekmann, A.F.; Lawson, N.D. Notch signalling limits angiogenic cell behaviour in developing zebrafish arteries. Nature 2007, 445, 781–784. [Google Scholar] [CrossRef]
- Nissen, L.J.; Cao, R.; Hedlund, E.M.; Wang, Z.; Zhao, X.; Wetterskog, D.; Funa, K.; Bråkenhielm, E.; Cao, Y. Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J. Clin. Invest. 2007, 117, 2766–2777. [Google Scholar] [CrossRef]
- Zhu, A.X.; Sahani, D.V.; Duda, D.G.; di Tomaso, E.; Ancukiewicz, M.; Catalano, O.A.; Sindhwani, V.; Blaszkowsky, L.S.; Yoon, S.S.; Lahdenranta, J.; Bhargava, P.; Meyerhardt, J.; Clark, J.W.; Kwak, E.L.; Hezel, A.F.; Miksad, R.; Abrams, T.A.; Enzinger, P.C.; Fuchs, C.S.; Ryan, D.P.; Jain, R.K. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J. Clin. Oncol. 2009, 18, 3027–3035. [Google Scholar]
- Burstein, H. J; Chen, Y.H.; Parker, L.M.; Savoie, J.; Younger, J.; Kuter, I.; Ryan, P.D.; Garber, J.E.; Chen, H,; Campos, S.M.; Shulman, L.N.; Harris, L.N.; Gelman, R.; Winer, E.P. VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin. Cancer Res. 2008, 14, 7871–7877. [Google Scholar] [CrossRef]
- Hanrahan, E.O; Ryan, A.J.; Mann, H.; Kennedy, S.J.; Langmuir, P.; Natale, R.B.; Herbst, R.S.; Johnson, B.E.; Heymach, J.V. Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin. Cancer Res. 2009, 15, 3600–3609. [Google Scholar] [CrossRef]
- Jonasch, E.; Corn, P.; Pagliaro, L.C.; Warneke, C.L.; Johnson, M.M.; Tamboli, P.Ng.C.; Aparicio, A.; Ashe, R.G.; Wright, J.J.; Tannir, N.M. Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer 2010, 116, 57–65. [Google Scholar]
- Jubb, A.M.; Hurwitz, H.I.; Bai, W.; Holmgren, E.B.; Tobin, P.; Guerrero, A.S.; Kabbinavar, F.; Holden, S.N.; Novotny, W.F.; Frantz, G.D.; Hillan, K.J.; Koeppen, H. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J. Clin. Oncol. 2006, 24, 217–227. [Google Scholar]
- Batchelor, T.T.; Sorensen, A.G.; di Tomaso, E.; Zhang, W.T.; Duda, D.G.; Cohen, K.S.; Kozak, K.R.; Cahill, D.P.; Chen, P.J.; Zhu, M.; Ancukiewicz, M.; Mrugala, M.M.; Plotkin, S.; Drappatz, J.; Louis, D.N.; Ivy, P.; Scadden, D.T.; Benner, T.; Loeffler, J.S.; Wen, P.Y.; Jain, R.K. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11, 83–95. [Google Scholar] [CrossRef]
- Burstein, H.J.; Elias, A.D.; Rugo, H.S.; Cobleigh, M.A.; Wolff, A.C.; Eisenberg, P.D.; Lehman, M.; Adams, B.J.; Bello, C.L.; DePrimo, S.E.; Baum, C.M.; Miller, K.D. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol. 2008, 26, 1810–1816. [Google Scholar] [CrossRef]
- Rini, B.I.; Michaelson, M.D.; Rosenberg, J.E.; Bukowski, R.M.; Sosman, J.A.; Stadler, W.M.; Hutson, T.E.; Margolin, K.; Harmon, C.S.; DePrimo, S.E.; Kim, S.T.; Chen, I.; George, D.J. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J. Clin. Oncol. 2008, 26, 3743–3748. [Google Scholar] [CrossRef]
- Drevs, J.; Siegert, P.; Medinger, M.; Mross, K.; Strecker, R.; Zirrgiebel, U.; Harder, J.; Blum, H.; Robertson, J.; Jürgensmeier, J.M.; Puchalski, T.A.; Young, H.; Saunders, O.; Unger, C. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 2007, 25, 3045–3054. [Google Scholar] [CrossRef]
- Motzer, R.J.; Michaelson, M.D.; Redman, B.G.; Hudes, G.R.; Wilding, G.; Figlin, R.A.; Ginsberg, M.S.; Kim, S.T.; Baum, C.M.; DePrimo, S.E.; Li, J.Z.; Bello, C.L.; Theuer, C.P.; George, D.J.; Rini, B.I. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2006, 24, 16–24. [Google Scholar] [CrossRef]
- Saltz, L.B.; Rosen, L.S.; Marshall, J.L.; Belt, R.J.; Hurwitz, H.I.; Eckhardt, S.G.; Bergsland, E.K.; Haller, D.G.; Lockhart, A.C.; Rocha Lima, C.M.; Huang, X.; DePrimo, S.E.; Chow-Maneval, E.; Chao, R.C.; Lenz, H.J. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J. Clin. Oncol. 2007, 25, 4793–4799. [Google Scholar] [CrossRef]
- Horowitz, N.; Penson, R.; Bouker, Y.; di Tomaso, E.; Fishman, A.; Ancukieviz, M.; Krasner, C.C.; Berlin, S.; Roche, M.; King, M.; Luzzi, A.; Lee, J.; Duda, D.G.; Jain, R.K. A multidisciplinary phase II study of bevacizumab combined with oxaliplatin, gemcitabine in women with recurrent mullerian carcinoma. AACR Ann. Abstr. 2008. Abstr. 4484. [Google Scholar]
- Willett, C.G.; Duda, D.G.; di Tomaso, E.; Boucher, Y.; Ancukiewicz, M.; Sahani, D.V.; Lahdenranta, J.; Chung, D.C.; Fischman, A.J.; Lauwers, G.Y.; Shellito, P.; Czito, B.G.; Wong, T.Z.; Paulson, E.; Poleski, M.; Vujaskovic, Z.; Bentley, R.; Chen, H.X.; Clark, J.W.; Jain, R.K. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J. Clin. Oncol. 2009, 18, 3020–3026. [Google Scholar]
- Dowlati, A.; Gray, R.; Sandler, A.B.; Schiller, J.H.; Johnson, D.H. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab – an Eastern Cooperative Oncology Group Study. Clin. Cancer Res. 2008, 14, 1407–1412. [Google Scholar]
- Heymach, J.V.; Desai, J.; Manola, J.; Davis, D.W.; McConkey, D.J.; Harmon, D.; Ryan, D.P.; Goss, G.; Quigley, T.; Van den Abbeele, A.D.; Silverman, S.G.; Connors, S.; Folkman, J.; Fletcher, C.D.; Demetri, G.D. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Clin. Cancer Res. 2004, 10, 5732–5740. [Google Scholar]
- Kiura, K.; Nakagawa, K.; Shinkai, T.; Eguchi, K.; Ohe, Y.; Yamamoto, N.; Tsuboi, M.; Yokota, S.; Seto, T.; Jiang, H.; Nishio, K.; Saijo, N.; Fukuoka, M. A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. J. Thorac. Oncol. 2008, 3, 386–393. [Google Scholar]
- Schneider, B.P.; Wang, M.; Radovich, M; Sledge, G.W.; Badve, S.; Thor, A.; Flockhart, D.A.; Hancock, B.; Davidson, N.; Gralow, J.; Dickler, M.; Perez, E.A.; Cobleigh, M.; Shenkier, T.; Edgerton, S.; Miller, K.D. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J. Clin. Oncol. 2008, 26, 4672–4678. [Google Scholar]
- Wilson, P. M.; Yang, D.; Shi, M.M.; Zhang, W.; Jacques, C.; Barrett, J. C.; Daneneberg, K.; Trarbach, T.; Folprecht, G.; Meinhardt, G.; Lenz, H.J. Use of intratumoral mRNA expression of genes involved in angiogenesis and HIF1 pathway to predict outcome to VEGFR tyrosine kinase inhibitor in patients enrolled in CONFIRM1 and CONFIRM2. J. Clin. Oncol. 2008, 26. Abstr. 4002. [Google Scholar]
- Schultheis, A.M.; Lurje, G.; Rhodes, K.E.; Zhang, W.; Yang, D.; Garcia, A.A.; Morgan, R.; Gandara, D.; Scudder, S.; Oza, A.; Hirte, H.; Fleming, G.; Roman, L.; Lenz, H.J. Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin. Cancer Res. 2008, 14, 7554–7563. [Google Scholar] [CrossRef]
- Kopetz, S.; Hoff, P.M.; Morris, J.S.; Wolff, R.A.; Eng, C.; Glover, K.Y.; Adinin, R.; Overman, M.J.; Valero, V.; Wen, S.; Lieu, C.; Yan, S.; Tran, H.T.; Ellis, L.M.; Abbruzzese, J.L.; Heymach, J.V. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J. Clin. Oncol. 2010, 28, 453–459. [Google Scholar] [CrossRef]
- Wedam, S.B.; Low, J.A.; Yang, S.X.; Chow, C.K.; Choyke, P.; Danforth, D.; Hewitt, S.M.; Berman, A.; Steinberg, S.M.; Liewehr, D.J.; Plehn, J.; Doshi, A.; Thomasson, D.; McCarthy, N.; Koeppen, H.; Sherman, M.; Zujewski, J.; Camphausen, K.; Chen, H.; Swain, S.M. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J. Clin. Oncol. 2006, 24, 769–777. [Google Scholar] [CrossRef]
- Bertolini, F.; Mancuso, P.; Shaked, Y.; Kerbel, R.S. Molecular and cellular biomarkers for angiogenesis in clinical oncology. Drug Discov. Today 2007, 12, 806–812. [Google Scholar] [CrossRef]
- Bertolini, F.; Shaked, Y.; Mancuso, P.; Kerbel, R.S. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat. Rev. Cancer 2006, 6, 835–845. [Google Scholar] [CrossRef]
- Seaman, S.; Stevens, J.; Yang, M.Y.; Logsdon, D.; Graff-Cherry, C.; St Croix, B. Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 2007, 11, 539–554. [Google Scholar] [CrossRef]
- Caveda, L.; Martin-Padura, I.; Navarro, P.; Breviario, F.; Corada, M.; Gulino, D.; Lampugnani, M.G.; Dejana, E. Inhibition of cultured cell growth by vascular endothelial cadherin (cadherin-5/VE-cadherin). J. Clin. Invest. 1996, 98, 886–893. [Google Scholar] [CrossRef]
- Carmeliet, P.; Lampugnani, M.G.; Moons, L.; Breviario, F.; Compernolle, V.; Bono, F.; Balconi, G.; Spagnuolo, R.; Oosthuyse, B.; Dewerchin, M.; Zanetti, A.; Angellilo, A.; Mattot, V.; Nuyens, D.; Lutgens, E.; Clotman, F.; de Ruiter, M.C.; Gittenberger-de Groot, A.; Poelmann, R.; Lupu, F.; Herbert, J.M.; Collen, D.; Dejana, E. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 1999, 98, 147–157. [Google Scholar] [CrossRef]
- Lambeng, N.; Wallez, Y.; Rampon, C.; Cand, F.; Christé, G.; Gulino-Debrac, D.; Vilgrain, I.; Huber, P. Vascular endothelial-cadherin tyrosine phosphorylation in angiogenic and quiescent adult tissues. Circ. Res. 2005, 96, 384–391. [Google Scholar] [CrossRef]
- Corada, M.; Zanetta, L.; Orsenigo, F.; Breviario, F.; Lampugnani, M.G.; Bernasconi, S.; Liao, F.; Hicklin, D.J.; Bohlen, P.; Dejana, E. A monoclonal antibody to vascular endothelial-cadherin inhibits tumor angiogenesis without side effects on endothelial permeability. Blood 2002, 100, 905–911. [Google Scholar] [CrossRef]
- Liao, F.; Doody, J.F.; Overholser, J.; Finnerty, B.; Bassi, R.; Wu, Y.; Dejana, E.; Kussie, P.; Bohlen, P.; Hicklin, D.J. Selective targeting of angiogenic tumor vasculature by vascular endothelial-cadherin antibody inhibits tumor growth without affecting vascular permeability. Cancer Res. 2002, 62, 2567–2575. [Google Scholar]
- Parker, B.S.; Argani, P.; Cook, B.P.; Liangfeng, H.; Chartrand, S.D.; Zhang, M.; Saha, S.; Bardelli, A.; Jiang, Y.; St Martin, T.B.; Nacht, M.; Teicher, B.A.; Klinger, K.W.; Sukumar, S.; Madden, S.L. Alterations in vascular gene expression in invasive breast carcinoma. Cancer Res. 2004, 64, 7857–7866. [Google Scholar] [CrossRef]
- Rabascio, C.; Muratori, E.; Mancuso, P.; Calleri, A.; Raia, V.; Foutz, T.; Cinieri, S.; Veronesi, G.; Pruneri, G.; Lampertico, P.; Iavarone, M.; Martinelli, G.; Goldhirsch, A.; Bertolini, F. Assessing tumor angiogenesis: increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells. Cancer Res. 2004, 64, 4373–4377. [Google Scholar] [CrossRef]
- Du, R.; Lu, K.V.; Petritsch, C.; Liu, P.; Ganss, R.; Passegué, E.; Song, H.; Vandenberg, S.; Johnson, R.S.; Werb, Z.; Bergers, G. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell. 2008, 13, 206–220. [Google Scholar] [CrossRef]
- Lyden, D.; Hattori, K.; Dias, S.; Costa, C.; Blaikie, P.; Butros, L.; Chadburn, A.; Heissig, B.; Marks, W.; Witte, L.; Wu, Y.; Hicklin, D.; Zhu, Z.; Hackett, N.R.; Crystal, R.G.; Moore, M.A.; Hajjar, K.A.; Manova, K.; Benezra, R.; Rafii, S. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 2001, 7, 1194–1201. [Google Scholar] [CrossRef]
- Shaked, Y.; Ciarrocchi, A.; Franco, M.; Lee, C.R.; Man, S.; Cheung, A.M.; Hicklin, D.J.; Chaplin, D.; Foster, F.S.; Benezra, R.; Kerbel, R.S. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 2006, 313, 1785–1787. [Google Scholar] [CrossRef]
- Blann, A.D.; Woywodt, A.; Bertolini, F.; Bull, T.M.; Buyon, J.P.; Clancy, R.M.; Haubitz, M.; Hebbel, R.P.; Lip, G.Y.; Mancuso, P.; Sampol, J; Solovey, A.; Dignat-George, F. Circulating endothelial cells. Biomarker of vascular disease. Thromb. Haemost. 2005, 93, 228–35. [Google Scholar]
- Mancuso, P.; Colleoni, M.; Calleri, A.; Orlando, L.; Maisonneuve, P.; Pruneri, G.; Agliano, A.; Goldhirsch, A.; Shaked, Y.; Kerbel, R.S.; Bertolini, F. Circulating endothelial cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 2006, 108, 452–459. [Google Scholar] [CrossRef]
- Furstenberger, G.; von Moos, R.; Lucas, R.; Thürlimann, B.; Senn, H.J.; Hamacher, J.; Boneberg, E.M. Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br. J. Cancer 2006, 94, 524–531. [Google Scholar] [CrossRef]
- Norden-Zfoni, A.; Desai, J.; Manola, J.; Beaudry, P.; Force, J.; Maki, R.; Folkman, J.; Bello, C.; Baum, C.; DePrimo, S.E.; Shalinsky, D.R.; Demetri, G.D.; Heymach, J.V. Bloodbased biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin. Cancer Res. 2007, 13, 2643–2650. [Google Scholar] [CrossRef]
- Dellapasqua, S.; Bertolini, F.; Bagnardi, V.; Campagnoli, E.; Scarano, E.; Torrisi, R.; Shaked, Y.; Mancuso, P.; Goldhirsch, A.; Rocca, A.; Pietri, E.; Colleoni, M. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J. Clin. Oncol. 2008, 26, 4899–4905. [Google Scholar] [CrossRef]
- Torrisi, R.; Bagnardi, V.; Cardillo, A.; Bertolini, F.; Scarano, E.; Orlando, L.; Mancuso, P.; Luini, A.; Calleri, A.; Viale, G.; Goldhirsch, A.; Colleoni, M. Preoperative bevacizumab combined with letrozole and chemotherapy in locallyadvanced ER- and/or PgR-positive breast cancer: clinical and biological activity. Br. J. Cancer 2008, 99, 1564–1571. [Google Scholar] [CrossRef]
- Shaked, Y.; Bertolini, F.; Man, S.; Rogers, M.S.; Cervi, D.; Foutz, T.; Rawn, K.; Voskas, D.; Dumont, D.J.; Ben-David, Y.; Lawler, J.; Henkin, J.; Huber, J.; Hicklin, D.J.; D'Amato, R.J.; Kerbel, R.S. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 2005, 7, 101–111. [Google Scholar]
- Eckelman, W.C.; Reba, R.C.; Kelloff, G.J. Targeted imaging: an important biomarker for understanding disease progression in the era of personalized medicine. Drug Discov. Today 2008, 13, 748–759. [Google Scholar] [CrossRef]
- Seaman, S.; Stevens, J.; Yang, M.Y.; Logsdon, D.; Graff-Cherry, C.; St Croix, B. Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 2007, 11, 539–554. [Google Scholar] [CrossRef]
- Yoder, M.C.; Mead, L.E.; Prater, D.; Krier, T.R.; Mroueh, K.N.; Li, F.; Krasich, R.; Temm, C.J.; Prchal, J.T.; Ingram, D.A. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 2007, 109, 1801–1809. [Google Scholar] [CrossRef]
- Case, J.; Mead, L.E.; Bessler, W.K.; Prater, D.; White, H.A.; Saadatzadeh, M.R.; Bhavsar, J.R.; Yoder, M.C.; Haneline, L.S.; Ingram, D.A. Human CD34+AC133+VEGFR-2+ cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors. Exp. Hematol. 2007, 35, 1109–1118. [Google Scholar] [CrossRef]
- Mancuso, P.; Antoniotti, P.; Quarna, J.; Calleri, A.; Rabascio, C.; Tacchetti, C.; Braidotti, P.; Wu, H.K.; Zurita, A.J.; Saronni, L.; Cheng, J.B.; Shalinsky, D.R.; Heymach, J.V.; Bertolini, F. Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry and molecular and ultrastructural analyses. Clin. Cancer Res. 2009, 15, 267–273. [Google Scholar] [CrossRef]
- Zhang, H.; Vakil, V.; Braunstein, M,; Smith, E.L.; Maroney, J.; Chen, L.; Dai, K.; Berenson, J.R.; Hussain, M.M.; Klueppelberg, U.; Norin, A.J.; Akman, H.O.; Ozçelik, T.; Batuman, O.A. Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood 2005, 105, 3286–3294. [Google Scholar] [CrossRef]
- De Palma, M.; Venneri, M.A.; Roca, C.; Naldini, L. Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat. Med. 2003, 9, 789–795. [Google Scholar] [CrossRef]
- Göthert, J.R.; Gustin, S.E.; van Eekelen, J.A.; Schmidt, U.; Hall, M.A.; Jane, S.M.; Green, A.R.; Göttgens, B.; Izon, D.J.; Begley, C.G. Genetically tagging endothelial cells in vivo: bone marrow-derived cells do not contribute to tumor endothelium. Blood 2004, 104, 1769–1777. [Google Scholar] [CrossRef]
- Duda, D.G.; Cohen, K.S.; Kozin, S.V.; Perentes, J.Y.; Fukumura, D.; Scadden, D.T.; Jain, R.K. Evidence for incorporation of bone marrow-derived endothelial cells into perfused blood vessels in tumors. Blood 2006, 107, 2774–2776. [Google Scholar] [CrossRef]
- Madlambayan, G.J.; Butler, J.M.; Hosaka, K.; Jorgensen, M.; Fu, D.; Guthrie, S.M.; Shenoy, A.K.; Brank, A.; Russell, K.J.; Otero, J.; Siemann, D.W.; Scott, E.W.; Cogle, C.R. Bone marrow stem and progenitor cell contribution to neovasculogenesis is dependent on model system with SDF-1 as a permissive trigger. Blood 2009, 114, 4310–4319. [Google Scholar] [CrossRef]
- Shaked, Y.; Ciarrocchi, A.; Franco, M.; Lee, C.R.; Man, S.; Cheung, A.M.; Hicklin, D.J.; Chaplin, D.; Foster, F.S.; Benezra, R.; Kerbel, R.S. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 2006, 313, 1785–1787. [Google Scholar] [CrossRef]
- Bertolini, F.; Paul, S.; Mancuso, P.; Monestiroli, S.; Gobbi, A.; Shaked, Y.; Kerbel, R.S. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res. 2003, 63, 4342–4346. [Google Scholar]
- Kerbel, R.S. Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 2006, 312, 1171–1175. [Google Scholar] [CrossRef]
- Ko, A.H.; Venook, A.P.; Bergsland, E.K.; Kelley, R.K.; Korn, W.M.; Dito, E.; Schillinger, B.; Scott, J.; Hwang, J.; Tempero, M.A. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother. Pharmacol. 2010. [Google Scholar] [CrossRef]
- Hurwitz, H.; Fehrenbacher, L.; Novotny, W.; Cartwright, T.; Hainsworth, J.; Heim, W.; Berlin, J.; Baron, A.; Griffing, S.; Holmgren, E.; Ferrara, N.; Fyfe, G.; Rogers, B.; Ross, R; Kabbinavar, F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004, 350, 2335–2342. [Google Scholar] [CrossRef]
- Scartozzi, M.; Galizia, E.; Chiorrini, S.; Giampieri, R.; Berardi, R.; Pierantoni, C.; Cascinu, S. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann. Oncol. 2009, 20, 227–230. [Google Scholar]
- Dahlberg, S.E.; Sandler, A.B.; Brahmer, J.R.; Schiller, J.H.; Johnson, D.H. Clinical Course of Advanced Non-Small-Cell Lung Cancer Patients Experiencing Hypertension During Treatment With Bevacizumab in Combination With Carboplatin and Paclitaxel on ECOG 4599. J. Clin. Oncol. 2010, 28, 949–954. [Google Scholar] [CrossRef]
© 2010 by the authors; licensee MDPI, Basel, Switzerland. This article is an Open Access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
Share and Cite
Rabascio, C.; Bertolini, F. Blood-Based Biomarkers for the Optimization of Anti-Angiogenic Therapies. Cancers 2010, 2, 1027-1039. https://doi.org/10.3390/cancers2021027
Rabascio C, Bertolini F. Blood-Based Biomarkers for the Optimization of Anti-Angiogenic Therapies. Cancers. 2010; 2(2):1027-1039. https://doi.org/10.3390/cancers2021027
Chicago/Turabian StyleRabascio, Cristina, and Francesco Bertolini. 2010. "Blood-Based Biomarkers for the Optimization of Anti-Angiogenic Therapies" Cancers 2, no. 2: 1027-1039. https://doi.org/10.3390/cancers2021027